ArticleInfection and drug resistance2018
Epidemiology and molecular characterization of multidrug-resistant
Article in Infection and drug resistance, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Review and analysis of the overlapping threats of carbapenem and polymyxin resistant E. coli and Klebsiella in Africa.Antimicrobial resistance and infection control · 2023Pooled it
- Specific killing and resensitization of pathogenic Escherichia coli strains carrying blaCTX-M-15 β-lactamase using targeted-antibacterial-plasmids (TAPs).Nucleic acids research · 2026Article
- Rabbits as a Reservoir of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial resistance and associated risk factors inVeterinary world · 2024Article
- Microbiological Characterisation of Community-Acquired Urinary Tract Infections in Bagamoyo, Tanzania: A Prospective Study.Tropical medicine and infectious disease · 2022Article
- The Evaluation of EazyplexAntibiotics (Basel, Switzerland) · 2022Article
- Colistin Resistance and ESBL Production inAntibiotics (Basel, Switzerland) · 2021Article
- Extended spectrum β lactamase-producing Enterobacteriaceae shedding by race horses in Ontario, Canada.BMC veterinary research · 2020Article
- Transferable Mechanisms of Quinolone Resistance from 1998 Onward.Clinical microbiology reviews · 2019Review
- Antibiotic-ResistantThe American journal of tropical medicine and hygiene · 2019Article
- Prevalence And Microbial Spectrum Of Patients With Spontaneous Bacterial Peritonitis In Northeast Nigeria - A Cross-Sectional Multi-Centre Study.Nigerian medical journal : journal of the Nigeria Medical AssociationReview
- Antibiotic-Resistance Genes inSaudi journal of medicine & medical sciencesArticle
- High prevalence of CTX-M-1 group in ESBL-producing enterobacteriaceae infection in intensive care units in southern Chile.The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious DiseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe emergence and spread of extended-spectrum β-lactamases (ESBLs), especially CTX-M, is an important public health problem with serious implications for low-income countries where second-line treatment is often unavailable. Knowledge of the local prevalence of ESBL is critical to define appropriate empirical therapeutic strategies for multidrug-resistant (MDR) organisms. This study aimed to assess and characterize the presence of ESBL and especially CTX-M-producing MATERIALS AND
methodsOne hundred and fifty-one
resultsApproximately 11% (17/151) of
conclusionOur data suggest the presence of a co-selection of third-generation cephalosporin-resistant determinants in the study area despite limited access to these antibiotics. This highlights the importance of continuous surveillance of antimicrobial resistance of both genetic elements of resistance and resistant isolates in order to monitor the emergence and trends of ESBL-producing isolates to promote adequate therapeutic strategies for the management of MDR bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.